RIG-301

RIG-301 is an inhaled mRNA therapy being developed by RIGImmune for the treatment of cystic fibrosis (CF). It utilizes the proprietary NEED™ (Nano-Emulsion Delivery) technology, which allows for the delivery of RNA compounds without the need for lipid nanoparticle (LNP) encapsulation. The therapy is designed to deliver wild-type Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mRNA directly to lung bronchial epithelial cells. By providing the genetic template for functional CFTR protein, RIG-301 aims to restore chloride transport and improve lung function in patients regardless of their specific CFTR mutation. Currently in preclinical development, RIG-301 is being prepared for Phase 1 clinical trials, with potential entry into the clinic expected in early 2026.